High prevalence of polypharmacy and nervous system medications in people with HIV: a cross-sectional analysis

1. Trickey, A. et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: A collaborative analysis of cohort studies. Lancet HIV 10, e295–e307 (2023).

   Google Scholar 

2. Mahy, M., Autenrieth, C. S., Stanecki, K. & Wynd, S. Increasing trends in HIV prevalence among people aged 50 years and older. AIDS 28, S453–S459 (2014).

   Google Scholar 

3. Guaraldi, G., Milic, J. & Mussini, C. Aging with HIV. Curr HIV/AIDS Rep 16, 475–481 (2019).

   Google Scholar 

4. Zicari, S. et al. Immune activation, inflammation, and non-AIDS Co-morbidities in HIV-infected patients under long-term ART. Viruses 11, 200 (2019).

   Google Scholar 

5. Feinstein, M. J. et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: A scientific statement from the American Heart Association. Circulation 140, (2019).

6. Van Epps, P. & Kalayjian, R. C. Human immunodeficiency virus and aging in the era of effective antiretroviral therapy. Infect. Dis. Clin. North Am. 31, 791–810 (2017).

   Google Scholar 

7. Fragkou, P. C. et al. Cardiovascular disease and risk assessment in people living with HIV: Current practices and novel perspectives. Hellenic J. Cardiol. 71, 42–54 (2023).

   Google Scholar 

8. Collins, L. F. et al. Aging-related comorbidity burden among women and men with or at-risk for HIV in the US, 2008–2019. JAMA Netw. Open 6, e2327584 (2023).

   Google Scholar 

9. Fuster-RuizdeApodaca, M. J. et al. Prevalence and patterns of illicit drug use in people living with HIV in Spain: A cross-sectional study. PLoS ONE 14, e0211252 (2019).

   Google Scholar 

10. Remien, R. H. et al. Mental health and HIV/AIDS. AIDS 33, 1411–1420 (2019).

    Google Scholar 

11. Eshun-Wilson, I. et al. Antidepressants for depression in adults with HIV infection. Cochrane Database Syst. Rev. 2018, (2018).

12. Mudra Rakshasa-Loots, A. Depression and HIV: a scoping review in search of neuroimmune biomarkers. Brain Commun. 5, (2023).

13. Mudra Rakshasa-Loots, A., Whalley, H. C., Vera, J. H. & Cox, S. R. Neuroinflammation in HIV-associated depression: evidence and future perspectives. Mol. Psychiatry 27, 3619–3632 (2022).

    Google Scholar 

14. Earnshaw, V. A. et al. HIV stigma, depressive symptoms, and substance use. AIDS Patient Care STDS 34, 275–280 (2020).

    Google Scholar 

15. World Health Organization. Medication Safety in Poly-Pharmacy. https ://apps.who.int/iris/bitst ream/handl e/10665 /32545 4/WHO-UHC-SDS-2019.11-eng.pdf?ua=1 (2019).

16. Edelman, E. J., Rentsch, C. T. & Justice, A. C. Polypharmacy in HIV: recent insights and future directions. Curr. Opin. HIV AIDS 15, 126–133 (2020).

    Google Scholar 

17. Rubin, L. H. et al. Degree of polypharmacy and cognitive function in older women with HIV. AIDS Res. Hum. Retrovir. 38, 571–579 (2022).

    Google Scholar 

18. Psomas, C. K. et al. Polypharmacy is associated with falls in women with and without HIV. JAIDS J. Acquir. Immune Defic. Syndr. 90, 351–359 (2022).

    Google Scholar 

19. Danjuma, M. I. et al. Prevalence and global trends of polypharmacy among people living with HIV: A systematic review and meta-analysis. Ther. Adv. Drug Saf. 13, 204209862210807 (2022).

    Google Scholar 

20. López-Centeno, B. et al. Polypharmacy and drug-drug interactions in people living with human immunodeficiency virus in the region of Madrid, Spain: A population-based study. Clin. Infect. Dis. 71, 353–362 (2020).

    Google Scholar 

21. Paudel, M. et al. Comorbidity and comedication burden among people living with HIV in the United States. Curr. Med. Res. Opin. 38, 1443–1450 (2022).

    Google Scholar 

22. Gimeno-Gracia, M., Crusells-Canales, M. J., Armesto-Gomez, F. J., Compaired-Turlan, V. & Rabanaque-Hernandez, M. J. Polypharmacy in older adults with human immunodeficiency virus infection compared with the general population. Clin. Interv. Aging 11, 1149–1157 (2016).

    Google Scholar 

23. Naito, T. et al. Comorbidities and co-medications among 28 089 people living with HIV: A nationwide cohort study from 2009 to 2019 in Japan. HIV Med. 23, 485–493 (2022).

    Google Scholar 

24. Altice, F. L., Kamarulzaman, A., Soriano, V. V, Schechter, M. & Friedland, G. H. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. The Lancet 376, 367–387 (2010).

25. Harris, P. A. et al. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377–381 (2009).

    Google Scholar 

26. Harris, P. A. et al. The REDCap consortium: Building an international community of software platform partners. J. Biomed. Inform. 95, 103208 (2019).

    Google Scholar 

27. Gutiérrez Ibarzábal, M. L., Berraondo Zabalegui, I., Bilbao Madariaga, J. L. & Gorroñogoitia Iturbe, A. I. Análisis y desarrollo del plan de actividades preventivas de atención primaria. Revisión de la oferta preferente y del programa informático de soporte. Vitoria-Gasteiz: Departamento de Sanidad y Consumo, Gobierno Vasco (2011).

28. Silla Stoel, M. & Rosón Hernández, B. Evaluación del consumo de alcohol y diagnóstico de patrón de consumo. Trastor. Adict. 11, 191–199 (2009).

29. University of Liverpool. HIV drug interactions. https://www.hivdruginteractions. org.

30. Smit, M. et al. Future challenges for clinical care of an ageing population infected with HIV: A modelling study. Lancet Infect. Dis. 15, 810–818 (2015).

    Google Scholar 

31. Subdirección General de Información Sanitaria. Salud Mental en datos: Prevalencia de los Problemas de Salud y Consumo de Psicofármacos y Fármacos Relacionados a Partir de Registros Clínicos de Atención Primaria. https://www.sanidad.gob.es/estadEstudios/estadisticas/estadisticas/estMinisterio/SIAP/Salud_mental_datos.pdf (2021).

32. Rasmussen, L. et al. Utilization of psychotropic drugs prescribed to persons with and without <scp>HIV</scp> infection: a <scp>D</scp> Anish nationwide population-based cohort study. HIV Med. 15, 458–469 (2014).

    Google Scholar 

33. Cholera, R. et al. Mind the Gap: Gaps in antidepressant treatment, treatment adjustments, and outcomes among patients in routine HIV care in a multisite U.S. clinical cohort. PLoS One 12, e0166435 (2017).

34. Kiely, K. M., Brady, B. & Byles, J. Gender, mental health and ageing. Maturitas 129, 76–84 (2019).

    Google Scholar 

35. Xu, Y. et al. Association between depression and HIV infection vulnerable populations in United States adults: A cross-sectional analysis of NHANES from 1999 to 2018. Front. Public Health 11, (2023).

36. de Pinho, C. S. N., Santana, R. D., Campos, E. de M. & Pires Neto, R. da J. Prevalence and factors associated with depression in people living with HIV/AIDS in a Brazilian metropolitan region. AIDS Care 34, 1580–1585 (2022).

37. Mitra, P., Jain, A. & Kim, K. HIV and AIDS in older adults: Neuropsychiatric changes. Curr. Psychiatry Rep. 24, 463–468 (2022).

    Google Scholar 

38. Skogen, V. et al. Prevalence of mental distress and factors associated with symptoms of major depression among people living with HIV in Norway. AIDS Care 36, 173–180 (2024).

    Google Scholar 

39. Pérez-Valero, I., Blanch, J. & Martínez, E. Perception of HIV physicians in Spain towards diagnosis and management of neuropsychiatric comorbidities in people with HIV. HIV Med. 23, 969–977 (2022).

    Google Scholar 

40. Brown, L. A., Mu, W., McCann, J., Durborow, S. & Blank, M. B. Under-documentation of psychiatric diagnoses among persons living with HIV in electronic medical records. AIDS Care 33, 311–315 (2021).

    Google Scholar 

41. Ballester-Arnal, R. et al. A Spanish study on psychological predictors of quality of life in people with HIV. AIDS Behav. 20, 281–291 (2016).

    Google Scholar 

42. GeSIDA. Consenso de GeSIDA sobre comorbilidad neuropsiquiátrica – cognitiva y VIH. https://gesida-seimc.org/wp-content/uploads/2020/07/Guia_GESIDA_ManejoClinicoComorbilidad.pdf (2020).

43. Crane, H. M. et al. Prevalence and factors associated with hazardous alcohol use among persons living with HIV across the US in the current era of antiretroviral treatment. AIDS Behav. 21, 1914–1925 (2017).

    Google Scholar 

44. Langan, K., Wall, M., Potts, W. & Himelhoch, S. Prevalence and potential predictors of gambling disorder among people living with HIV. AIDS Care 31, 421–426 (2019).

    Google Scholar 

45. Shiau, S., Arpadi, S. M., Yin, M. T. & Martins, S. S. Patterns of drug use and HIV infection among adults in a nationally representative sample. Addict. Behav. 68, 39–44 (2017).

    Google Scholar 

46. Fluharty, M., Taylor, A. E., Grabski, M. & Munafò, M. R. The association of cigarette smoking with depression and anxiety: A systematic review. Nicotine Tob. Res. 19, 3–13 (2017).

    Google Scholar 

47. Fiorentini, A. et al. Substance-induced psychoses: An updated literature review. Front. Psychiatry 12, (2021).

48. Ma, L., Steinberg, J. L., Moeller, F. G., Johns, S. E. & Narayana, P. A. Effect of cocaine dependence on brain connections: Clinical implications. Expert Rev. Neurother. 15, 1307–1319 (2015).

    Google Scholar 

49. Mena, Á. Central nervous system disorders in HIV-infected individuals using distinct antiretroviral drugs. AIDS Rev. 23, (2023).

50. Hoffmann, C. & Llibre, J. M. Neuropsychiatric adverse events with Dolutegravir and other integrase strand transfer inhibitors. AIDS Rev. 21, (2019).

51. Cid-Silva, P. et al. Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in <scp>HIV</scp> -infected patients: Efficacy, safety and tolerance. Basic Clin. Pharmacol. Toxicol. 121, 442–446 (2017).

    Google Scholar 

52. Elzi, L. et al. Adverse events of raltegravir and dolutegravir. AIDS 31, 1853–1858 (2017).

    Google Scholar 

53. European Pharmacovigilance Assessment Report. European Medicines Agency (EMA). Prezista. 68–69 https://www.ema.europa.eu/en/documents/product-information/prezista-epar-product-information_en.pdf (2024).

54. European Public Assessment Report. European Medicines Agency (EMA). Symtuza. 48 https://www.ema.europa.eu/en/documents/product-information/symtuza-epar-product-information_en.pdf (2024).

55. Altunal, L. N. et al. Prevalence of polypharmacy and potential drug-drug interactions associated with risk factors in the era of HIV integrase inhibitors: A prospective clinical study. AIDS Patient Care STDS 37, 138–145 (2023).

    Google Scholar 

56. Deutschmann, E. et al. Prevalence of potential drug-drug interactions in patients of the Swiss HIV cohort study in the era of HIV integrase inhibitors. Clin. Infect. Dis. 73, e2145–e2152 (2021).

    Google Scholar 

Download references